An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.

Haematologica
Hanny Al-SamkariVivek N Iyer

Abstract

Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is a rare multisystem vascular disorder causing chronic gastrointestinal bleeding, epistaxis, and severe anemia. Bevacizumab, an anti-vascular endothelial growth factor antibody, may be effective to treat bleeding in HHT. This international, multicenter, retrospective study evaluated the use of systemic bevacizumab to treat HHT-associated bleeding and anemia at 12 HHT treatment centers. Hemoglobin, epistaxis severity score, red cell units transfused, and intravenous iron infusions before and after treatment were evaluated using paired means testing and mixed-effects linear models. 238 HHT patients received bevacizumab for a median of 12 (range, 1-96) months. Compared with pretreatment, bevacizumab increased mean hemoglobin by 3.2 g/dL (95% CI, 2.9-3.5 g/dL) [mean hemoglobin 8.6 (8.5, 8.8) g/dL versus 11.8 (11.5, 12.1) g/dL, p.

Citations

Nov 22, 2020·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Patrick G NorthupDominique C Valla
Mar 30, 2021·Journal of Neurological Surgery. Part B, Skull Base·Daniel B RootmanLiza M Cohen
May 1, 2021·Diagnostics·Margaux Van WynsbergheCarole Henique
May 1, 2021·Journal of Thrombosis and Haemostasis : JTH·Nathan Watson, Hanny Al-Samkari
Jun 26, 2021·The Lancet. Haematology·Hanny Al-Samkari
Jul 27, 2021·Case Reports in Gastrointestinal Medicine·Muaaz MasoodHumberto Sifuentes
Aug 27, 2021·Journal of Thrombosis and Haemostasis : JTH·Hanny Al-Samkari
Aug 28, 2021·International Journal of Molecular Sciences·Katharina SchimmelEdda Spiekerkoetter
Oct 26, 2021·Journal of Thrombosis and Thrombolysis·Abraham Z CheloffHanny Al-Samkari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.